Authors
Christian Marth, Marie-Ange Mouret-Reynier, Domenica Lorusso, Claire Cropet, Philipp Harter, Eva Guerra, Takashi Matsumoto, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Coriolan Lebreton, Nikolaus De Gregorio, Anna Maria Mosconi, María Jesús Rubio, Hugues Bourgeois, Peter A Fasching, Anne-Claire Hardy-Bessard, Dominik Denschlag, Eric Pujade-Lauraine, Isabelle Ray-Coquard
Publication date
2023/9/1
Source
International Journal of Gynecologic Cancer
Volume
33
Issue
Suppl 3
Publisher
BMJ Specialist Journals
Description
Introduction/Background
In PAOLA-1/ENGOT-ov25 (NCT02477644), maintenance PARP inhibitor (PARPi) olaparib+bevacizumab improved progression-free survival (PFS) in patients with homologous recombination-deficient (HRD+) advanced ovarian cancer (Ray-Coquard. NEJM 2019;381:2416–28). Post-hoc analysis showed the efficacy of subsequent chemotherapy at relapse was reduced in patients who progressed during versus after olaparib treatment (Harter. Presented at ASCO 2023).
In the OReO/ENGOT-ov38 trial (NCT03106987), olaparib rechallenge conferred a modest but statistically significant PFS benefit in patients with platinum-sensitive ovarian cancer (Pujade-Lauraine. Ann Oncol 2021;32:S1308–9), the majority of whom had received initial PARPi therapy in the relapsed setting and, therefore, were most likely to have progressed under PARPi maintenance. We explored PARPi rechallenge in …
Total citations
20242
Scholar articles
C Marth, MA Mouret-Reynier, D Lorusso, C Cropet… - 2023